ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 977

Nurse Led Safe Switching from Original Reference Product Infliximab to Biosimalar in Patients with Juvenile Idiopathic Arthritis and Uveitis – a Single Centre Experience Including Baseline and Post Switch Infliximab Levels and Antibodies

Andrew Fell1, Emma Carson1, Gillian Coyle1, Neil Martin1, Jo Walsh1 and Janet Gardner-Medwin2, 1Paediatic Rheumatology, Royal hospital for Children, Glasgow, United Kingdom, 2School of Medicine, Dentistry & Nursing, Child Health, University of Glasgow, Glasgow, United Kingdom

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: biosimilars, infliximab, Juvenile idiopathic arthritis (JIA) and uveitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: 3S115 ACR/ARHP Abstract: Pediatric Rheum (976–981)

Session Type: ACR/ARHP Combined Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Original Reference Product (ORP) Infliximab lost market exclusivity in europe in early 2015. The Scottish National Health service (SNHS), runs a national procurement system called the Clinical Advisory Panel (CAP). CAP recommended all patients new to Infliximab were commenced on biosimilar Infliximab (BIFX). To encourage switching a project run by NHS Healthcare Improvement Scotland, produced targets for biosimilar uptake and advised the setting up of local drug efficiencies committees. In early 2017 we had a cohort of young people remaining on ORP that we are asked to consider their infliximab preparation.

Methods: The Royal Hospital for Children in Glasgow (RHCG ) had a cohort of children principally with Juvenile Idiopathic Arthritis (JIA) and uveitis remaining on ORP infliximab. This use is off market label both with the European Medicine Agency and the Federal drug administration. After a review of evidence the RHCG Rheumatology team regarding the safety of switching elected to create a patient evaluation protocol for switching and patient information. Patients were identified from the Health-board wide IT system. Within the same time period a trial project for measuring trough drug levels and antibodies was introduced in Scotland using the Grifols promonitor system. It was decided to monitor these variables whilst switching. A drug and antibody level was to be taken immediately preceding the planned dose of Biosimilar Infliximab, then again 3 to 4 doses after switching or not. All patients and families were sent out information regarding the possible swap and met individually by a member of the nursing team to discuss the possible change of preparation. At point of switch offer, 12 young people were identified on ORP; 8 with JIA + Uveitis, 2 with idiopathic Uveitis, 1 with sympathetic Uveitis, 1 with JIA. All had clinically inactive disease, from last clinical review.

Results: Of the young people; 6 completed the switch, however 1 was found clinically flaring with active uveitis 4 days after switching. Their pre switch drug levels were low with high antibodies causing a change of therapy and are now in clinical remission. The five who completed the switch remain in clinical remission, this group is too small for any statistical interpretation but drug levels and antibodies are comparable pre and post switch. The 6 who did not swap at original offer to BIFX; 1 did not qualify for switching to biosimilar, 1 elected not to switch, 1 stopped, 1 changed therapy due to geography, 2 changed therapy due to personal choice. Within this group of 6, 3 maintained no active disease, 2 remaining on ORP and one swapped to Adalimumab. 3 developed active disease, 1 has commenced Adalimumab, 2 have attempted multiple biologics and have returned recently to IFX one on ORP and one BIFX. Both are returning to low disease activity.Of the initial group of 12, 4 are on ORP, 5 on BIFX, 3 are on Adalimumab.Pre and post switch period Infliximab levels and antibodies are available for 8 young people. They are comparable regardless of switch.Conclusion: Switching was not associated with any adverse events. Disease activity measures for those remaining on IFX were unchanged on either ORP or Biosimilar. Stopping Infliximab was associated with disease flare.


Disclosure: A. Fell, AbbVie Inc., 8; E. Carson, None; G. Coyle, None; N. Martin, None; J. Walsh, None; J. Gardner-Medwin, None.

To cite this abstract in AMA style:

Fell A, Carson E, Coyle G, Martin N, Walsh J, Gardner-Medwin J. Nurse Led Safe Switching from Original Reference Product Infliximab to Biosimalar in Patients with Juvenile Idiopathic Arthritis and Uveitis – a Single Centre Experience Including Baseline and Post Switch Infliximab Levels and Antibodies [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/nurse-led-safe-switching-from-original-reference-product-infliximab-to-biosimalar-in-patients-with-juvenile-idiopathic-arthritis-and-uveitis-a-single-centre-experience-including-baseline-a/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nurse-led-safe-switching-from-original-reference-product-infliximab-to-biosimalar-in-patients-with-juvenile-idiopathic-arthritis-and-uveitis-a-single-centre-experience-including-baseline-a/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology